Dermira Inc. Daily Stock Analysis

Daily Stock Analysis, DERM, Dermira Inc, priceseries

Dermira Inc. Daily Stock Analysis
Stock Information
Open
18.75
Close
18.75
High
18.77
Low
18.74
Previous Close
18.74
Daily Price Gain
0.01
YTD High
19.48
YTD High Date
Jan 10, 2020
YTD Low
12.50
YTD Low Date
Jan 6, 2020
YTD Price Change
3.96
YTD Gain
26.77%
52 Week High
19.48
52 Week High Date
Jan 10, 2020
52 Week Low
5.25
52 Week Low Date
Oct 16, 2019
52 Week Price Change
10.61
52 Week Gain
130.34%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Sep 6. 2017
24.20
Sep 22. 2017
26.32
12 Trading Days
8.75%
Link
LONG
Dec 6. 2017
24.70
Jan 2. 2018
27.18
17 Trading Days
10.03%
Link
LONG
May 4. 2018
9.51
May 21. 2018
10.35
11 Trading Days
8.84%
Link
LONG
Jun 6. 2018
9.27
Jun 25. 2018
10.03
13 Trading Days
8.16%
Link
LONG
Jul 6. 2018
9.91
Jul 17. 2018
10.67
7 Trading Days
7.64%
Link
LONG
Sep 26. 2018
10.59
Oct 10. 2018
11.78
10 Trading Days
11.26%
Link
LONG
Nov 18. 2019
7.70
Nov 27. 2019
8.21
7 Trading Days
6.62%
Link
LONG
Dec 9. 2019
9.09
Jan 6. 2020
13.98
18 Trading Days
53.75%
Link
LONG
Jan 7. 2020
15.45
Feb 7. 2020
18.79
22 Trading Days
21.60%
Link
Company Information
Stock Symbol
DERM
Exchange
NasdaqGS
Company URL
http://www.dermira.com
Company Phone
650 421 7200
CEO
Thomas G. Wiggans
Headquarters
California
Business Address
275 MIDDLEFIELD ROAD, SUITE 150, MENLO PARK, CA 94025
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001557883
About

Dermira, Inc. is a biopharmaceutical company that focuses on bringing differentiated products to dermatologists and patients. It also focuses on medical dermatology, a field that concentrates on therapeutic solutions to treat skin conditions, such as psoriasis, hyperhidrosis and acne. Dermira was founded by Thomas G. Wiggans, Eugene Andrew Bauer, Luis C. Peña, and Christopher M. Griffith on August 18, 2010 and is headquartered in Menlo Park, CA.

Description

Dermira, Inc., a biopharmaceutical company, engages in identifying, developing, and commercializing therapies to enhance the lives of patients with dermatologic diseases primarily in the United States. The company's late-stage product candidates include Cimzia, an injectable biologic tumor necrosis factor-alpha inhibitor to treat various inflammatory diseases, as well as to treat patients with moderate-to-severe chronic plaque psoriasis; Glycopyrronium tosylate, a small-molecule anticholinergic product that is in Phase III clinical trial for the treatment of primary axillary hyperhidrosis or excessive underarm sweating; and Olumacostat glasaretil, a small-molecule sebum inhibitor, which is in Phase III clinical trial to treat acne vulgaris or acne. It has a collaboration agreement with UCB Pharma S.A. for the development and commercialization of Cimzia. The company was formerly known as Skintelligence, Inc. and changed its name to Dermira, Inc. in September 2011. Dermira, Inc. was founded in 2010 and is headquartered in Menlo Park, California.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading